SCHEMBL1208368

SCHEMBL1208368

CCOc1ccccc1CCC(=O)Nc1sc2c(c1C#N)CCC(COC(=O)OCc1cncs1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
MAPT P10636 7/20 0.43
POLB P06746 3/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RECQL P46063 1/20 0.40
ALOX15 P16050 2/20 0.40
NPC1 O15118 1/20 0.40
MAPK1 P28482 1/20 0.40
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 1/20 0.39
PTPN5 P54829 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12895665 0.91 ALDH1A1 (0.45) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1207045 0.91 MAPT (0.43) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL14292917 0.91 MAPT (0.39) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL16160189 0.90 ALDH1A1 (0.44) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1207724 0.90 ALDH1A1 (0.52) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1207827 0.89 ALDH1A1 (0.45) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1208503 0.86 ALDH1A1 (0.45) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1207711 0.84 ALDH1A1 (0.51) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL1207708 0.83 MAPT (0.52) ALDH1A1MAPTPOLBRAB9AMEN1
SCHEMBL14292927 0.83 ALDH1A1 (0.44) ALDH1A1MAPTRAB9AALOX15NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150527-B2 Metalloenzyme inhibitor compounds INNOCRIN PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-20140303157-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2014-10-09 US disclosed
US-20110044938-A1 TETRAHYDROBENZOTHIOPHENE DERIVATIVES NYCOMED GMBH (DE) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303157-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ALDH1A1 289/4885MAPT 2507/4885POLB 1777/4885
US-20110044938-A1 TETRAHYDROBENZOTHIOPHENE DERIVATIVES BAX, BCL2, BAD ALDH1A1 316/4885MAPT 865/4885POLB 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.